glp-1 receptor agonist and dpp-4 inhibitor combination contraindicated versus kidney and cardiovascular outcomes in clinical practice in type-2 diabetes Renoprotective Effects of DPP-4 Inhibitors
Description
[DOI] [PubMed] [Google Scholar] 24.Ponce M.B., Shields B.E
Cureus, 15(7), e42153
And on top of that, I spoke to Rozalina McCoy, whos a University of Maryland researcher
Cardiovascular events reported during the PIONEER program with oral semaglutide
a , Thermal stability (Tm) comparison of GLP-1R wild-type and StaR (containing the following point mutations: T207E, Q211A, D215R, L232F, G295A, T298A, C329A, P358A, G361A, H363V and V405A)
Physiological Reviews , 87(4), 14091439
